Ph.D., Non-Executive Chairman
Ian was appointed a Director on 24 November 2014 and as Non-Executive Chairman on 11 May 2015. He is currently Non-Executive Chairman of three life sciences companies including AIM-quoted Horizon Discovery Group Plc, which provides gene-editing tools to support translational genomics and the development of personalised medicine, Elucigene, focussed on the development and commercialisation of laboratory based molecular diagnostic tests and Biosurfit SA, focussed on development and commercialisation of point-of-care diagnostic products. Dr Gilham was formerly Chief Executive Officer of Axis-Shield Plc.
Chief Executive Officer
David was appointed a Director and Chief Executive on March 1, 2016. He has over 20 years of international commercial and operational experience in the diagnostics and medical devices field. He previously served as General Manager of Leica Biosystems Amsterdam and Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, product development, and commercial launches for diagnostic tests. Prior to Leica, David’s roles included Point-of-Care, molecular, and central laboratory marketing and commercialisation responsibilities at Siemens Healthcare Diagnostics, Bayer Diagnostics, and Visible Genetics.
Chief Financial Officer
Matthew was appointed Chief Financial Officer on December 13th 2016. He has over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes. Prior to that, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.
Ph.D., Non-Executive Director
Trained as a biochemist, Roger has almost 35 years' experience in the healthcare and biotechnology sector, particularly in the areas of strategic planning and business development. International business management with ICI Plc and AstraZeneca Plc. As Executive Director of Global Licensing at AstraZeneca, he personally completed 24 transactions, including strategic alliances with Abgenix and CAT, and acquisitions of KuDOS Pharmaceuticals and CAT. He operates as a Board Adviser in the biotech sector.
Ph.D., Non-Executive Director
Robert has been a Non-Executive Director of the Company since 2004. He brings with him a wealth of expertise in partnering and licensing negotiations with both small biotechnology and large pharmaceutical companies. Prior to his retirement he was Director, Global Licensing at AstraZeneca. He is also a non-executive Director of Phico Therapeutics Ltd.
Tom has 35 years of global sales and marketing experience in the diagnostics sector. He most recently worked for Alere Inc. in Africa for 11 years before retiring in 2017. At Alere he held a range of executive posts including President of Africa, President Commercial Operations for Africa, and Business Development Director for Africa; and led the introduction and successful commercialisation of a number of key HIV screening and HIV patient management point of care diagnostics technologies.
Prior to joining Alere Inc., Tom held senior commercial roles at Trinity Biotech (Ireland) including Marketing and Sales Director (Global) and Business Development Director for Africa, Middle East and India. Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits.
Tom studied Microbiology at Glasgow Caledonian University and completed a National Diploma in Microbiology at the South African Institute of Medical Research in Johannesburg, South Africa.